Literature DB >> 9704866

Prolactin response to D-fenfluramine in outpatients with major depression.

R J Kavoussi1, J Kramer, R L Hauger, E F Coccaro.   

Abstract

There is much indirect evidence of serotonin abnormalities in patients with major depression. Unfortunately, previous reports of serotonin challenge studies in depressed patients have yielded conflicting results. In order to test the serotonin hypothesis of depression, the authors compared 20 outpatients with major depressive disorder to 20 normal control subjects using prolactin response to D-fenfluramine as a measure of central serotonergic (5-HT) functioning. Patients were free of histories of suicidal behavior and had no Axis II disorders. There were no significant differences in prolactin responses between depressed patients and control subjects to challenge with D-fenfluramine at a dose of 0.5 mg/kg. The possible implications of these findings are discussed with respect to theories regarding biological vulnerabilities to major depression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704866     DOI: 10.1016/s0165-1781(98)00039-0

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse.

Authors:  Jacob P R Jacobsen; Ivan O Medvedev; Marc G Caron
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

2.  Research on serotonin and suicidal behavior: neuroendocrine and molecular approaches.

Authors:  Humberto Corrêa; Marco Aurélio Romano-Silva; Fabrice Duval; Ana Carolina Campi-Azevedo; Vivtor Lima; Jean-Paul Macher
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

3.  Serotonergic and noradrenergic function in depression: clinical correlates.

Authors:  F Duval; M C Mokrani; P Bailey; H Corrêa; M A Crocq; T Son Diep; J P Macher
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.